These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 22451330)

  • 1. The neuropathology of genetic Parkinson's disease.
    Poulopoulos M; Levy OA; Alcalay RN
    Mov Disord; 2012 Jun; 27(7):831-42. PubMed ID: 22451330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alzheimer's disease tau is a prominent pathology in LRRK2 Parkinson's disease.
    Henderson MX; Sengupta M; Trojanowski JQ; Lee VMY
    Acta Neuropathol Commun; 2019 Nov; 7(1):183. PubMed ID: 31733655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations.
    Alcalay RN; Levy OA; Waters CC; Fahn S; Ford B; Kuo SH; Mazzoni P; Pauciulo MW; Nichols WC; Gan-Or Z; Rouleau GA; Chung WK; Wolf P; Oliva P; Keutzer J; Marder K; Zhang X
    Brain; 2015 Sep; 138(Pt 9):2648-58. PubMed ID: 26117366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic analysis of Mendelian mutations in a large UK population-based Parkinson's disease study.
    Tan MMX; Malek N; Lawton MA; Hubbard L; Pittman AM; Joseph T; Hehir J; Swallow DMA; Grosset KA; Marrinan SL; Bajaj N; Barker RA; Burn DJ; Bresner C; Foltynie T; Hardy J; Wood N; Ben-Shlomo Y; Grosset DG; Williams NM; Morris HR
    Brain; 2019 Sep; 142(9):2828-2844. PubMed ID: 31324919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced LRRK2 in association with retromer dysfunction in post-mortem brain tissue from LRRK2 mutation carriers.
    Zhao Y; Perera G; Takahashi-Fujigasaki J; Mash DC; Vonsattel JPG; Uchino A; Hasegawa K; Jeremy Nichols R; Holton JL; Murayama S; Dzamko N; Halliday GM
    Brain; 2018 Feb; 141(2):486-495. PubMed ID: 29253086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resequencing analysis of five Mendelian genes and the top genes from genome-wide association studies in Parkinson's Disease.
    Benitez BA; Davis AA; Jin SC; Ibanez L; Ortega-Cubero S; Pastor P; Choi J; Cooper B; Perlmutter JS; Cruchaga C
    Mol Neurodegener; 2016 Apr; 11():29. PubMed ID: 27094865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of LRRK2, SNCA, Parkin, PINK1, and DJ-1 in Zambian patients with Parkinson's disease.
    Yonova-Doing E; Atadzhanov M; Quadri M; Kelly P; Shawa N; Musonda ST; Simons EJ; Breedveld GJ; Oostra BA; Bonifati V
    Parkinsonism Relat Disord; 2012 Jun; 18(5):567-71. PubMed ID: 22445250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LRRK2 activity does not dramatically alter α-synuclein pathology in primary neurons.
    Henderson MX; Peng C; Trojanowski JQ; Lee VMY
    Acta Neuropathol Commun; 2018 May; 6(1):45. PubMed ID: 29855356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuropathology of genetic synucleinopathies with parkinsonism: Review of the literature.
    Schneider SA; Alcalay RN
    Mov Disord; 2017 Nov; 32(11):1504-1523. PubMed ID: 29124790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pathology of familial Parkinson's disease].
    Wakabayashi K; Takahashi H
    Brain Nerve; 2007 Aug; 59(8):851-64. PubMed ID: 17713121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cognitive and psychiatric symptoms in genetically determined Parkinson's disease: a systematic review.
    Piredda R; Desmarais P; Masellis M; Gasca-Salas C
    Eur J Neurol; 2020 Feb; 27(2):229-234. PubMed ID: 31686421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Substantia nigra hyperechogenicity with LRRK2 G2019S mutations.
    Brüggemann N; Hagenah J; Stanley K; Klein C; Wang C; Raymond D; Ozelius L; Bressman S; Saunders-Pullman R
    Mov Disord; 2011 Apr; 26(5):885-8. PubMed ID: 21312285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and pathological characteristics of LRRK2 G2019S patients with PD.
    Poulopoulos M; Cortes E; Vonsattel JP; Fahn S; Waters C; Cote LJ; Moskowitz C; Honig LS; Clark LN; Marder KS; Alcalay RN
    J Mol Neurosci; 2012 May; 47(1):139-43. PubMed ID: 22194196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The LRRK2 G2019S mutation as the cause of Parkinson's disease in Ashkenazi Jews.
    Thaler A; Ash E; Gan-Or Z; Orr-Urtreger A; Giladi N
    J Neural Transm (Vienna); 2009 Nov; 116(11):1473-82. PubMed ID: 19756366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CSF total and oligomeric α-Synuclein along with TNF-α as risk biomarkers for Parkinson's disease: a study in LRRK2 mutation carriers.
    Majbour NK; Aasly JO; Hustad E; Thomas MA; Vaikath NN; Elkum N; van de Berg WDJ; Tokuda T; Mollenhauer B; Berendse HW; El-Agnaf OMA
    Transl Neurodegener; 2020 May; 9(1):15. PubMed ID: 32375873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrospinal fluid biomarkers and clinical features in leucine-rich repeat kinase 2 (LRRK2) mutation carriers.
    Vilas D; Shaw LM; Taylor P; Berg D; Brockmann K; Aasly J; Marras C; Pont-Sunyer C; Ríos J; Marek K; Tolosa E
    Mov Disord; 2016 Jun; 31(6):906-14. PubMed ID: 27041685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.
    Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ
    Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fall risk and gait in Parkinson's disease: the role of the LRRK2 G2019S mutation.
    Mirelman A; Heman T; Yasinovsky K; Thaler A; Gurevich T; Marder K; Bressman S; Bar-Shira A; Orr-Urtreger A; Giladi N; Hausdorff JM;
    Mov Disord; 2013 Oct; 28(12):1683-90. PubMed ID: 24123150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Olfactory deficits and cardiac 123I-MIBG in Parkinson's disease related to the LRRK2 R1441G and G2019S mutations.
    Ruiz-Martínez J; Gorostidi A; Goyenechea E; Alzualde A; Poza JJ; Rodríguez F; Bergareche A; Moreno F; López de Munain A; Martí Massó JF
    Mov Disord; 2011 Sep; 26(11):2026-31. PubMed ID: 21611983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carriers of both GBA and LRRK2 mutations, compared to carriers of either, in Parkinson's disease: Risk estimates and genotype-phenotype correlations.
    Yahalom G; Greenbaum L; Israeli-Korn S; Fay-Karmon T; Livneh V; Ruskey JA; Roncière L; Alam A; Gan-Or Z; Hassin-Baer S
    Parkinsonism Relat Disord; 2019 May; 62():179-184. PubMed ID: 30573413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.